Company’s 36-month beta value is 1.13.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TARS is 30.44M, and currently, short sellers hold a 25.95% ratio of that floaft. The average trading volume of TARS on May 09, 2024 was 701.62K shares.
TARS) stock’s latest price update
Tarsus Pharmaceuticals Inc (NASDAQ: TARS)’s stock price has decreased by -5.30 compared to its previous closing price of 37.35. However, the company has seen a 2.14% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-08 that Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants David Nakasone – Head of Investor Relations Bobby Azamian – Chief Executive Officer and Chairman Aziz Mottiwala – Chief Commercial Officer Jeff Farrow – Chief Financial Officer and Chief Strategy Officer Sesha Neervannan – Chief Operating Officer Conference Call Participants Eddie Hickman – Guggenheim Securities Balaji – Barclays Francois Brisebois – Oppenheimer Jason Gerberry – Bank of America Andrea Tan – Goldman Sachs Corey Jubinville – Life Sci Capital Operator Good afternoon, and welcome to Tarsus’s First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
TARS’s Market Performance
Tarsus Pharmaceuticals Inc (TARS) has seen a 2.14% rise in stock performance for the week, with a -1.42% decline in the past month and a 13.41% surge in the past quarter. The volatility ratio for the week is 5.80%, and the volatility levels for the past 30 days are at 5.85% for TARS. The simple moving average for the last 20 days is 2.98% for TARS stock, with a simple moving average of 52.31% for the last 200 days.
Analysts’ Opinion of TARS
Many brokerage firms have already submitted their reports for TARS stocks, with Goldman repeating the rating for TARS by listing it as a “Neutral.” The predicted price for TARS in the upcoming period, according to Goldman is $19 based on the research report published on November 20, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see TARS reach a price target of $44. The rating they have provided for TARS stocks is “Outperform” according to the report published on July 18th, 2023.
TARS Trading at 2.96% from the 50-Day Moving Average
After a stumble in the market that brought TARS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.45% of loss for the given period.
Volatility was left at 5.85%, however, over the last 30 days, the volatility rate increased by 5.80%, as shares sank -6.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.62% lower at present.
During the last 5 trading sessions, TARS rose by +3.21%, which changed the moving average for the period of 200-days by +98.17% in comparison to the 20-day moving average, which settled at $34.22. In addition, Tarsus Pharmaceuticals Inc saw 74.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TARS starting from Azamian Bobak R., who sale 10,415 shares at the price of $30.60 back on Mar 18 ’24. After this action, Azamian Bobak R. now owns 26,456 shares of Tarsus Pharmaceuticals Inc, valued at $318,699 using the latest closing price.
Neervannan Seshadri, the Chief Operating Officer of Tarsus Pharmaceuticals Inc, sale 4,879 shares at $30.60 during a trade that took place back on Mar 18 ’24, which means that Neervannan Seshadri is holding 64,767 shares at $149,297 based on the most recent closing price.
Stock Fundamentals for TARS
Current profitability levels for the company are sitting at:
- -4.37 for the present operating margin
- 0.93 for the gross margin
The net margin for Tarsus Pharmaceuticals Inc stands at -4.11. The total capital return value is set at -0.62. Equity return is now at value -69.71, with -55.01 for asset returns.
Based on Tarsus Pharmaceuticals Inc (TARS), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -3.89. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -87.83.
Currently, EBITDA for the company is -142.28 million with net debt to EBITDA at 1.4. When we switch over and look at the enterprise to sales, we see a ratio of 35.68. The receivables turnover for the company is 1.85for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.93.
Conclusion
In a nutshell, Tarsus Pharmaceuticals Inc (TARS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
